Patent Application
20230028933
The present discloser relates to the field of metabolic engineering, in particular to a method for constructing a 3-aminoisobutyric acid producing strain, and in particular to a method for producing 3-aminoisobutyric acid by genetic strain.
3-aminoisobutyric acid, also known as β-aminoisobutyric acid ((β-AIB) or 3-amino-2-methylpropionic acid, has the chemical formula as follows:
3-aminoisobutyric acid is a non-protein amino acid, a metabolite of thymine and valine, excreted in the urine. The R-configuration is derived from thymine and the S configuration is derived from valine, and the R-configuration in the urine accounts for more than 90%. It has been found that β-AIB, as the first representative small molecule of myokine in the non-adrenergic activator family of white adipose tissue thermogenic process, has a good pharmaceutical potential for type II diabetes and metabolic diseases. In addition, 3-aminoisobutyric acid can be used as a chemical raw material and a pharmaceutical intermediate. As a raw material for organic synthesis, it has more than 20 kinds of upstream products and more than 10 kinds of downstream products. The application and research in the field of pharmaceutical intermediates is very extensive.
At present, 3-aminoisobutyric acid is mainly prepared by chemical methods. Although the yield of the product is high, an expensive catalyst and a large amount of hydrochloric acid are required in the synthesis steps, and at the same time, highly toxic cyanide is generated, which causes great pollution to the environment. As the requirements of environmental protections increase, it is necessary to develop environmentally friendly green production methods. CN108998401A disclosed a method for producing β-AIB by the fermentation of Escherichia coli engineering strain in 2018. In the patent, three genes of ptsG, fumAC and fumB were knocked out from wild strain MG1655, and three genes were highly expressed including L-aspartic acid α-decarboxylase gene panD, aspartase gene aspA and methyltransferase gene C24MTgm.The obtained engineering strain can produce 100 mg/L β-AIB in the shake flask, which provides the possibility for biological preparation of β-AIB. But the amount of β-AIB produced by the engineered strain is low, so that there is still much room for improvement.
In order to overcome the problem of pollution caused by the chemical synthesis method of 3-aminoisobutyric acid and the low production of 3-aminoisobutyric acid by fermentation, the present invention utilized an S-adenosyl-L-methionine δ24-sterol-C-methyltransferase mutant C24MTgm-M11 from Glycine max, constructed its overexpression vector pSU-lacIqTrc-C24MTgm-M11, and introduced it into MG1655 (ΔptsG ΔfumA CΔ fumB, panD, aspA) (see in CN108998401A), the obtained expression strain can significantly increase the yield of 3-aminoisobutyric acid fermentation.
Specifically, the present invention including the following technical solutions:
A method for constructing a 3-aminoisobutyric acid producing strain, comprising the steps:
A. Construction of an expression plasmid pSU-lacIqTrc-C24MTgm-M11 of S-adenosyl-L-methionine δ24-sterol-C-methyltransferase mutant C24MTgm-M11 derived from Glycine max;
B. The plasmid obtained in the step A was transformed into strain MG1655 (ΔptsGΔfumACΔfumB, panD, aspA) to obtain a genetic engineered strain MG1655 (ΔptsGΔfumAC fumB, panD, aspA, C24MTgm-M11).
In one embodiment, the present invention provides herein a methyltransferase enzyme mutant C24MTgm-M11, which is derived from a wild type enzyme C24MTgm of SEQ ID NO: 1, wherein the proline 135 is replaced by alanine, leucine 136 is replaced by alanine and phenylalanine 213 is replaced by serine.
Preferably, the methyltransferase enzyme mutant C24MTgm-M11 comprises the amino acid sequence of SEQ ID NO: 3.
In other embodiments, the present invention provides polynucleotide encoding the enzyme mutant C24MTgm-M11, comprising the nucleic acid sequence of SEQ ID NO: 4.
In other embodiments, the present invention provides a methyltransferase enzyme mutant expression vector, comprising the polynucleotide of claim 3.
Preferably, the vector is pSU-lacIqTrc-C24MTgm-M11 plasmid comprising the polynucleotide of the present invention.
In other embodiments, the present invention provides a host cell comprising the vector of the present invention.
Preferably, the host cell is E coli MG1655 (ΔptsG ΔfumAC ΔfumB, panD, aspA, C24MTgm-M11).
The present invention also provides a use of the methyltransferase enzyme mutant C24MTgm-M11 or the vector or the host cell of the present invention for producing 3- the method for producing 3-aminoisobutyric acid is fermentation.
the use of the present invention comprises the following steps:
(a) Acquisition of C24MTgm-M11 gene,
(b) Construction of C24MTgm-M11 expression vector,
(c) Construction the host cell,
(d) inoculating the host cell into a culture medium, and then adding glucose as a substrate, which is converted to form 3-aminoisobutyric acid by the host cell.
Preferably, the fermentation medium consists of the following: (NH4)2SO4 15 g/L, KH2PO4 5.0 g/L, Na2HPO4.12H2O 15 g/L, MgSO4.7H2O 1.0 g/L, yeast extract 1.0 g/L, glucose 20 g/L, pH 7.0.
The genetic strain can be directly used as a fermentation intermediate to produce 3-aminoisobutyric acid by fermentation, it can also be used as a starting strain for screening to obtain a new strain with further improved production capacity of 3-aminoisobutyric acid.
The invention adopts Escherichia coli as an initial strain, and uses molecular biological technology to modify the genome, and the recombinant engineering strain can obtain 3-aminoisobutyric acid by fermentation. It was verified by shake flask fermentation that the highest yield of 3-aminoisobutyric acid can reach 870 mg/L, indicating that the method of the present invention has industrial application potential.
While the present disclosure is capable of being embodied in various forms, the description below of several embodiments is made with the understanding that the present disclosure is to be considered as an exemplification of the claimed subject matter, and is not intended to limit the appended claims to the specific embodiments illustrated and/or described, and should not be construed to limit the scope or breadth of the present disclosure. The headings used throughout this disclosure are provided for convenience only and are not to be construed to limit the claims in any way. Embodiments illustrated under any heading may be combined with embodiments illustrated under any other heading.
The present invention relates to the addition amount, content and concentration of various substances, wherein the percentages are referred to as mass percentages unless otherwise specified.
In the present invention, the term “E.coli MG1655”, “original strain MG1655” have the same meaning and refer to the original strain which has not been genetically engineered.
In the present invention, the term “gene knockout strain MG1655” and “MG1655(ΔptsG ΔfumAC ΔfumB)” have the same meaning and refer to the strain in which the ptsG, fumAC, fumB genes have been knocked out in the E. coli MG1655 genome.
C24MTgm-M11 mutant in the present invention is S-adenosyl-L-methionine δ24-sterol-C-methyltransferase mutant constructed from wild-type S-adenosyl-L-methionine δ24- sterol-C-methyltransferase (C24MTgm). It is a new protein with several individual amino acids replaced in the SEQ ID NO: 1. Therefore, the term “C-methyltransferase” herein may also be referred to as “S-adenosyl-L-methionine δ24-sterol-methyltransferase mutant”, which means the same meaning and can be used interchangeably.
The C24MTgm-M11 mutant from soybean was obtained by a rationally designed directed evolution method. C24MTgm-M11 mutant, which is derived form a wild type C24MTgm, wherein proline is replaced by alanine at position 135, leucine is replaced by alanine at position 136 and phenylalanine is replaced by serine at position 213. After the above steps, and a mutant having the amino acid sequence of SEQ ID NO: 3 in the present invention was obtained.
In the present invention, the nucleic acid sequence SEQ ID NO: 4 is obtained by a site-directed mutagenesis using the nucleic acid sequence SEQ ID NO: 2 of the wild type C24MTgm gene as a template.
The present invention constructs the nucleic acid sequence of C24MTgm-M11 into the expression vector of pSU-lacIqTrc-C24MTgm-M11 containing the trc promoter, and transforms the expression plasmid into MG1655 (ΔptsG ΔfumAC ΔfumB, panD, aspA) to obtain transformant MG1655 (ΔptsG ΔfumAC ΔfumB, panD, aspA, C24MTgm-M11).
It was found that the ability of transformant MG1655 (AptsG AfumAC AfumB, panD, aspA, C24MTgm-M11) to produce 3-aminoisobutyric acid was significantly improved compared to the MG1655 (AptsG AfumAC AfumB, panD, aspA, C24MTgm) constructed by wild-type gene C24MTgm.
In the present invention, the whole gene synthesis, primer synthesis and sequencing was done by Suzhou GENEWIZ, Inc. Molecular biology experiments include plasmid construction, restriction enzyme digestion, ligation, competent cell preparation, transformation, medium preparation, etc., mainly refer to “Molecular Cloning: A Laboratory Manual ” (Third Edition), J.F. Sambrook, D.W. Russell edited, translated by Huang Peitang et al., Science Press, Beijing, 2002).
For example, the methods of transformation of competent cell and the preparation of competent cell are all referred to Chapter 1, page 96 of the “Molecular Cloning: A Laboratory Manual” (Third Edition). Specific experimental conditions can be determined by simple tests if necessary.
Enzyme KOD FX for PCR involved in the examples was purchased from Toyobo Co., Ltd., and the restriction endonuclease was purchased from Thermofisher, Gibson assembly kit was purchased from NEB, and the Axygen DNA purification and plasmid extraction kit was purchased from Corning Incorporated Company. The experimental operation was carried out according to the product instruction manual.
LB medium: 10 g/L tryptone, 10 g/L sodium chloride, 5.0 g/L yeast extract (solid medium added 20 g/L agar powder, pH=7.0)
The fermentation medium: (NH4)2SO4 15 g/L, KH2PO4 5.0 g/L, Na2HPO4·12H2O 15 g/L, MgSO4·7H2O 1.0 g/L, 1.0 g/L yeast extract, 20 g/L glucose, pH=7.0
In the following examples, when an antibiotic-containing medium was used, the final concentration of the antibiotic was ampicillin 100 μg/ml, and chloramphenicol 40 μg/ml. The corresponding antibiotic was added according to the characteristics of the transformed plasmid.
20X electro transfer stock solution: 80 g/L glycine, 2% Tween 80.
The solid medium was statically cultured at 37° C. The liquid medium was cultured at 37° C and shaken at 230 rpm.
Pre-column derivatization of the sample with o-phthalaldehyde as a derivatizing agent, the column is Agilent SB-C18, and the mobile phase is sodium acetate (concentration is 2.871 g/L) in 30% of methanol aqueous solution, temperature of column is 30° C, detection wavelength is 334 nm, detection time is 10 min, retention time is 5.1 min.
Plasmid pSU-lacIqTrc-C24MTgm disclosed in patent CN108998401A was used as template. KOD-FX PCR amplification was carried out with C24MTgm-F/135A136A-R, 135A136A-F/213 S-R, 213 S-F/C24MTgm-R as primers, respectively. The fragment C24MTgm-P1/C24MTgm-P2/C24MTgm-P3 was obtained.
And then three fragments of C24MTgm-P1/C24MTgm-P2/C24MTgm-P3 were used as templates, C24MTgm-F/C24MTgm-R was used as primer for overlapping PCR, and finally obtain C24MTgm- Mll gene. The primer sequences used above are as follows:
The pSU-lacIqTrc-C24MTgm plasmid was digested with BamHI/HindIII to recover a 4351 bp fragment. The C24MTgm-M11 gene fragment constructed in Example 1 was digested with BamHI/HindIII and cloned into the recombinant plasmid fragment to obtain C24MTgm-M11 expression vector. The pSU-lacIqTrc-C24MTgm-M11 expression plasmid has a structure as shown in
The pSU-lacIqTrc-C24MTgm-M11 expression plasmid constructed in Example 2 was transformed into the E. coli strain MG1655 (AptsGAfumACAfumB, panD, aspA) by electroporation (the strain was from the patent CN108998401A), and then the strain MG1655 (ΔptsG ΔfumAC ΔfumB, panD, aspA, C24MTgm-M11) was obtained.
The fermentation can use glucose as a carbon source.
For example, the fermentation medium consisted of the following: (NH4)2SO4 15 g/L, KH2PO4 5.0 g/L, Na2HPO4·12H2O 15 g/L, MgSO4·7H2O 1.0 g/L, yeast extract 1.0 g/L, glucose 20 g/L, pH 7.0.
The original strains MG1655, MG1655 (ΔptsGΔfumACΔfumB, panD, aspA, C24MTgm), and MG1655 (ΔptsGΔfumACΔfumB, panD, aspA, C24MTgm-M11) were cultured and fermented respectively. The fermentation medium was loaded with 30/250 ml, 37 ° C, 230 rpm. Fermentation was carried out for 24-32 h, and the content of 3-aminoisobutyric acid was measured.
Analytical method for 3-aminoisobutyric acid: pre-column derivatization of the sample with o-phthalaldehyde as a derivatizing agent, the column is Agilent SB-C18, and the mobile phase is sodium acetate (concentration is 2.871 g/L) in 30% of methanol aqueous solution, temperature of column is 30 ° C, detection wavelength is 334 nm, detection time is 10 min, retention time is 5.1 min.
The results showed that strain MG1655 cannot produce 3-aminoisobutyric acid; strain MG1655 (ΔptsGΔfumACΔfumB, panD, aspA, C24MTgm) could produce 82 mg/L of 3-aminoisobutyric acid; strain MG1655 (ΔptsGΔfumACΔfumB, panD, aspA, C24MTgm-M11) can produce 480 mg/L 3-aminoisobutyric acid. Compared to the wild type strain C24MTgm, the strain containing mutant C24MTgm-M11 has a significantly improved ability to produce 5.8-fold of 3-aminobutyric acid.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/CN2019/121262 | 11/27/2019 | WO |
